Recombinant Bacterial Effector Proteins for Targeted Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory disorders, such as skin inflammation, primarily address symptoms without targeting the underlying inflammatory pathways, leading to non-specific effects and potential toxicity, while existing cosmeceuticals lack defined targets and are complex mixtures with uncertain efficacy.
Innovation Solution
Compositions comprising paired peptides of bacterial effector polypeptides linked to a protein transduction domain are used to specifically target and modulate inflammatory pathways, such as NFkB/JNK/p38, by delivering recombinant effector proteins directly to inflamed cells via a protein transduction domain, optionally with targeting moieties for precise delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If non-specific drugs like corticosteroids are used to treat inflammatory symptoms, then symptoms (swelling, redness, pain) are relieved, but the underlying inflammatory pathways remain activated and toxicity may occur
Solution Approach 1:
The patent segments the treatment approach by using multiple individual effector proteins (NleE, NleC, NleD, NleB, NleH, YopM, YopE, YopH, YopJ, YopP, SspH1, OspG, OspF, IpaH9.8, IpaH1.4, IpaH2.5, IpaH4.5, IpaH7.8, SlrP) that each target specific components of the inflammatory pathway (NFkB, JNK, p38). This segmentation allows precise targeting of different inflammatory mechanisms rather than using broad-spectrum non-specific drugs.
Solution Approach 2:
The patent applies local quality by using effector proteins with specific binding affinities for particular inflammatory pathway components. Each effector protein has defined molecular targets within the NFkB/JNK/p38 pathways, allowing selective inhibition of specific inflammatory signals while preserving other cellular functions, thereby reducing non-specific toxicity.
2Adaptability or versatility
If complex mixtures of active compounds are used in cosmeceuticals, then a broad range of ingredients are provided, but the compositions lack defined targets and have uncertain efficacy
Solution Approach 1:
The patent extracts and isolates specific effector proteins from complex bacterial systems, purifying individual proteins (NleE, NleC, NleD, etc.) that have defined molecular targets. This extraction approach replaces complex mixtures with precisely characterized proteins that can be tracked and measured for their specific anti-inflammatory effects on NFkB/JNK/p38 pathways.
Solution Approach 2:
The patent changes the parameter of molecular specificity by using recombinant effector proteins with known amino acid sequences and defined binding specificities. Each protein's molecular weight, sequence identity, and target binding characteristics are precisely controlled, enabling accurate measurement of their effects on specific inflammatory pathways.
3Ease of operation
If treatments do not target the actual pathways causing inflammation, then simplicity is maintained, but the treatments cannot affect the underlying mechanism of activation
Solution Approach 1:
The patent uses effector proteins as intermediary molecules that bridge the gap between simple administration and complex pathway modulation. These proteins serve as mediators that specifically bind to and inhibit components of the NFkB/JNK/p38 pathways, translating simple topical application into precise molecular intervention without requiring complex delivery systems.
Data Source
AI summary
Provided herein are methods and compositions comprising a set of paired peptides comprising a first bacterial effector polypeptide or fragment thereof linked to a second bacterial effector polypeptide or fragment thereof. The paired peptides can be linked to a protein transduction domain. The compositions can be formulated as pharmaceuticals. The compositions are useful for the treatment of inflammatory disorders.